GPEI

PharmaJet, Nigeria's National Primary Health Care Development Agency and Health-focused Consortium Launch Assessment of the PharmaJet Tropis Vaccine Delivery System

Retrieved on: 
Tuesday, March 7, 2023
Medical Supplies, Health, Medical Devices, Infectious Diseases, Research, Science, Biotechnology, Child, Immunization, Polio vaccine, ID, USAID, PATH, Jhpiego, Vaccine hesitancy, IPV, Injection, GPEI, United, Use, International development, Needle, Multimedia, Caregiver, WHO, Global Polio Eradication Initiative, Vaccine, TROPI

PharmaJet and co-investigators from the National Primary Health Care Development Agency (NPHCDA), Jhpiego , PATH and the Sydani Group met in Lagos Nigeria and have finalized the study design, outlined the timelines, protocol, and tools for the study.

Key Points: 
  • PharmaJet and co-investigators from the National Primary Health Care Development Agency (NPHCDA), Jhpiego , PATH and the Sydani Group met in Lagos Nigeria and have finalized the study design, outlined the timelines, protocol, and tools for the study.
  • It will assess the health impact, cost, and feedback from providers and caregivers of using Tropis for ID delivery of inactivated poliovirus vaccine (IPV) compared to standard intramuscular delivery using needle and syringe.
  • The PharmaJet Tropis NFIS is a WHO prequalified, hand-held device that delivers precise ID injections without needles.
  • “We are thrilled to be working with NPHCDA, Jhpiego, PATH, and Sydani on this study,” noted Paul LaBarre, Vice President of Global Business Development, PharmaJet.

PharmaJet Needle-free System Selected to Deliver Intradermal Polio Vaccine in Nigerian Campaign

Retrieved on: 
Tuesday, November 8, 2022
Health, Medical Supplies, Medical Devices, CE marking, United Nations, Review, Global Polio Eradication Initiative, U.S. FDA, LGA, World Health Organization, Injection, Sias, GPEI, Vaccine, Certification, Stockholm Environment Institute US Center, Gavi, Centers for Disease Control and Prevention, UNICEF, Public health, OPV, PQS, Polio, World, Use, Partnership, Bill & Melinda Gates Foundation, IPV, System, CDC, Rotary International, Multimedia, Research, Paralysis, WHO, CEO

View the full release here: https://www.businesswire.com/news/home/20221108005025/en/

Key Points: 
  • View the full release here: https://www.businesswire.com/news/home/20221108005025/en/
    Kangethe Ngure, Regional Director for Africa, PharmaJet, demonstrating Tropis device use to trainers in Sokoto, Nigeria.
  • The Nigeria pilot campaign will combine the nOPV2 oral vaccine with an intradermal polio vaccine (1/5 of a full IPV dose) administered with the PharmaJet Tropis NFIS.
  • We are pleased to be selected for the polio vaccine campaign in Nigeria to curtail the spread of cVDPV2, said Chris Cappello, President and CEO of PharmaJet.
  • Intradermal administration of polio vaccine with the PharmaJet Tropis NFIS has already been successfully used in mass vaccination campaigns in Somalia, Pakistan, Cuba, and The Gambia.

Bloomberg Philanthropies Commits Additional $50 Million to Eradicate Polio

Retrieved on: 
Tuesday, October 18, 2022
CDC, Degenerative disease, World Health Summit, Education, Risk, Government, City, Public health, YouTube, GPEI, Bloomberg Philanthropies, Rotary International, Twitter, Instagram, WPV, Centers for Disease Control and Prevention, Stockholm Environment Institute US Center, WHO, Health Resources and Services Administration, World, Global Polio Eradication Initiative, Poliovirus, Bill & Melinda Gates Foundation, World Health Organization, UNICEF, Polio, Vaccination, Child, Paralysis, Bloomberg, COVID-19, 2022 ICC Men's T20 World Cup, Global health, Vaccine, Facebook, Environment, Injury

NEW YORK, Oct. 18, 2022 /PRNewswire/ -- Bloomberg Philanthropies today announced an additional $50 million commitment to the Global Polio Eradication Initiative (GPEI) reinforcing its dedication to GPEI's mission to complete the global eradication of polio. This renewal of support comes at a time when polio is rebounding, following a fall in vaccination rates during the COVID-19 pandemic and a heightened risk of a polio resurgence, and brings Bloomberg Philanthropies total commitment to GPEI to $225 million since 2013.

Key Points: 
  • NEW YORK, Oct. 18, 2022 /PRNewswire/ -- Bloomberg Philanthropies today announced an additional $50 million commitment to the Global Polio Eradication Initiative (GPEI) reinforcing its dedication to GPEI's mission to complete the global eradication of polio.
  • "Until we eradicate polio from the world, it poses a risk to people everywhere," said Michael R. Bloomberg, founder of Bloomberg Philanthropies and WHO Global Ambassador for Noncommunicable Diseases and Injuries.
  • "Since 2013, Bloomberg Philanthropies has been glad to support the critically important work of the Global Polio Eradication Initiative and now, as polio outbreaks threaten the critical progress we've made, we're recommitting to the urgent fight to end polio for good."
  • "Eradicating polio will require the full support of the global health community," said Dr. Kelly Henning, who leads Public Health programs at Bloomberg Philanthropies.

SINOVAC Polio Vaccine Prequalified by WHO

Retrieved on: 
Thursday, June 9, 2022
Infectious Diseases, Biotechnology, Pharmaceutical, Health, GPEI, World Health Organization, UN, Polio, OPV, Global Polio Eradication Initiative, Research, Food, Immunization, Infection, Influenza A virus subtype H1N1, United Nations, Poliovirus, VAPP, Polio eradication, Sinovac Biotech, Mouth, Environment, Hepatitis A, Pain, WHO, Fever, Chickenpox, Motor neuron, Vaccine, Feces, Campus Biotech, Saliva, COVID-19, NASDAQ, Prevalence, CoronaVac, Water, Public health, Mumps, Profile, EV71, World

The vaccine will be available for United Nations (UN) agencies to purchase to support the global polio endgame strategy.

Key Points: 
  • The vaccine will be available for United Nations (UN) agencies to purchase to support the global polio endgame strategy.
  • The vaccine can be used sequentially with oral polio attenuated live vaccine (OPV).
  • With the impact of the global COVID-19 pandemic, countries where wild polio strains still exist have experienced an increasing prevalence of polio cases.
  • SINOVAC has been continually dedicating itself to new vaccine research and development, with more combined and new technology vaccine products in the pipeline.